Affiliation:
1. Istituto di Anatomia e Istologia Patologica, Divisione di Ricerche sul Cancro
2. Istituto di Igiene, Università di Perugia
Abstract
Metronidazole, which is widely used in the treatment of «Trichomonas vaginalis», «Entamoeba histolytica» and «Giardia lamblia» infections, was administered to BALB/c mice by stomach tube in an aqueous solution at a dose rate of 2 mg/day for 100 days (total 200 mg) to test its carcinogenicity. The treatment induced a significant increase in lung tumors in male mice (p < 0.001) and provoked the appearance of lymphomas in females (p < 0.001). Although there is insufficient evidence to pass judgement on the potential carcinogenicity of metronidazole in man, the results of this and other investigations reported in the literature have demonstrated that metronidazole develops carcinogenic activity in rats and mice.
Subject
Cancer Research,Oncology,General Medicine
Reference14 articles.
1. Lack of Evidence for Cancer Due to Use of Metronidazole
2. Cancer after Metronidazole
3. GoodmanL.S., GilmanA.: The Pharmacological Basis of Therapeutics, pp. 1072–1073, 1086–1088, MacMillan, New York, 1975.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献